Straits Times Index
3,330.09 +11.64 (+0.35%) S&P 500
5,290.32 -14.40 (-0.27%) Dow
38,765.02 -304.57 (-0.78%) Nasdaq
16,954.25 +33.46 (+0.20%) Bitcoin USD
67,655.25 -2,254.30 (-3.22%) CMC Crypto 200
1,461.88 -34.58 (-2.31%)
NVO Jun 2024 72.500 call
- Benzinga
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Novo Nordisk A/S (NYSE:NVO) has disclosed that it retains approximately 60% of the list price of its diabetes and obesity medications, Ozempic and Wegovy, in the U.S. after accounting for rebates and fees paid to intermediaries. This revelation comes amid intensifying scrutiny over the cost of these blockbuster drugs. In a recent letter to Senator Bernie Sanders, the European drug maker expressed willingness to collaborate with lawmakers to tackle systemic issues hindering patients’ access to me
- Zacks
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- Reuters
Analysis-Weight-loss drug forecasts jump to $150 billion as supply grows
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s. "It is very unusual to have a medicine that is capturing the imagination of millions of people," said Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science. Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers, he said.
